Baseline characteristics
Of the 20 patients, 65% (n=13) were female, the mean age was 55 ± 17 years, and 60% (n=12) had a diagnosis of Idiopathic PAH (IPAH), 30% (n=6) PAH associated with connective tissue disease (CTD-PAH) and 10%(n=2) were defined as other. Patients reported NYHA FC II symptoms in 50% (n=10) and FC III in 50% (n=10) at baseline. Baseline risk assessment was stratified as low in 25% (n=5), intermediate in 65% (n=13) and high risk in 10% (n=2). Dual combination therapy was prescribed in 90% (n=18) and triple combination therapy consisting of inhaled iloprost in 10% (n=2). Co-morbidities and additional baseline medications were common and are displayed in Table 1 .